| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2022 |
|
|
2021 |
|
| |
|
Year Ended October 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Net income (loss): |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(5,776 |
) |
|
$ |
(5,673 |
) |
| Cancer Vaccines |
|
|
(4,889 |
) |
|
|
(4,559 |
) |
| Anti-Viral Therapeutics |
|
|
(3,075 |
) |
|
|
(2,928 |
) |
| Other |
|
|
(31 |
) |
|
|
32 |
|
| Total |
|
$ |
(13,771 |
) |
|
$ |
(13,128 |
) |
| |
|
|
|
|
|
|
|
|
| Net income (loss) |
|
$ |
(13,771 |
) |
|
$ |
(13,128 |
) |
| Total operating costs and expenses |
|
$ |
13,875 |
|
|
$ |
13,648 |
|
| Less non-cash share-based compensation |
|
|
(6,655 |
) |
|
|
(8,058 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
7,220 |
|
|
$ |
5,590 |
|
| |
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash share based compensation: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
3,206 |
|
|
$ |
2,422 |
|
| Cancer Vaccines |
|
|
2,355 |
|
|
|
1,642 |
|
| Anti-Viral Therapeutics |
|
|
1,634 |
|
|
|
1,080 |
|
| Other |
|
|
25 |
|
|
|
446 |
|
| Total |
|
$ |
7,220 |
|
|
$ |
5,590 |
|
| Operating costs and expenses excluding non-cash share based compensation |
|
$ |
7,220 |
|
|
$ |
5,590 |
|
| |
|
2022 |
|
|
2021 |
|
| |
|
October 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
16,921 |
|
|
$ |
15,068 |
|
| Cancer Vaccines |
|
|
9,442 |
|
|
|
13,277 |
|
| Anti-Viral Therapeutics |
|
|
3,811 |
|
|
|
7,368 |
|
| Other |
|
|
238 |
|
|
|
544 |
|
| Total |
|
$ |
30,412 |
|
|
$ |
36,257 |
|
| Total assets |
|
$ |
30,412 |
|
|
$ |
36,257 |
|
|